Publications - Mark Liebow, M.D.

Back to Research Profile

1. Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, Schildkraut J, Berchuck A, Couch FJ, Wang X, Fridley BL, Ovarian Cancer Association Consortium, Gentry-Maharaj A, Menon U, Hogdall E, Kjaer S, Whittemore A, DiCioccio R, Song H, Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer 2009 Oct 20; 101(8):1461-8. Epub 2009 Sep 08.
   View PubMed
2. Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, Dogan A, Witzig TE, Ansell SM, Habermann TM, Kay NE, Slager SL. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol 2009 Jun; 145(5):614-23. Epub 2009 Mar 30.
   View PubMed
3. Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, Saag M, Squires KE, Weddle A, Rainey J, Zerehi MR, Ralston JF, Fleming DA, Bronson D, Cooke M, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, HIV Policy: The Path Forward - A Joint Position Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009 May 15; 48(10):1335-44.
   View PubMed
4. Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, Ziesmer S, Liebow M, Macon WR, Dillon SR, Witzig TE, Cerhan JR, Ansell SM. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009 May 15; 69(10):4217-24. Epub 2009 Apr 21.
   View PubMed
5. White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, Schildkraut JM, Cunningham JM, Kelemen LE, Pankratz VS, Rider DN, Liebow M, Hartmann LC, Sellers TA, Goode EL. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer 2009; 9:170. Epub 2009 Jun 06.
   View PubMed
6. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG, Habermann TM, Ansell SM, Slager SL. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008 Nov; 17(11):3161-9.
   View PubMed
7. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, DiCioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PDP, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008 Jul 15; 123(2):380-8.
   View PubMed
8. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008 Jul 15; 123(2):380-8.
   View PubMed
9. Kelemen LE, Sellers TA, Schildkraut JM, Cunningham JM, Vierkant RA, Pankratz VS, Fredericksen ZS, Gadre MK, Rider DN, Liebow M, Goode EL. Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 2008 Apr 1; 68(7):2498-506.
   View PubMed
10. Sellers TA, Huang Y, Cunningham J, Goode EL, Sutphen R, Vierkant RA, Kelemen LE, Fredericksen ZS, Liebow M, Pankratz VS, Hartmann LC, Myer J, Iversen ES Jr, Schildkraut JM, Phelan C. Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008 Feb; 17(2):397-404.
    View PubMed
11. Elkin PL, Brown SH, Balas A, Temesgen Z, Wahner-Roedler D, Froehling D, Liebow M, Trusko B, Rosenbloom ST, Poland G. Biosurveillance evaluation of SNOMED CT's terminology (BEST Trial): coverage of chief complaints. Stud Health Technol Inform 2008; 136:797-802.
    View PubMed
12. Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007 Dec 15; 110(13):4455-63. Epub 2007 Sep 07.
    View PubMed
13. Slager SL, Kay NE, Fredericksen ZS, Wang AH, Liebow M, Cunningham JM, Vachon CM, Call TG, Cerhan JR. Susceptibility genes and B-chronic lymphocytic leukaemia. Br J Haematol 2007 Dec; 139(5):762-71.
    View PubMed
14. Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen ZS, Olson JE, Cunningham J, Taylor W, Liebow M, McPherson C, Hartmann LC, Pal T, Adjei AA. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005 Nov; 14(11 Part 1):2536-43.
    View PubMed
15. Liebow M. What will the new medicare drug benefit mean for Minnesota physicians? Minn Med 2005 Mar; 88(3):38-41.
    View PubMed
16. Liebow M. Dr. Liebow or Mr. Liebling? Minn Med 2004 Oct; 87(10):31, 51.
    View PubMed
17. Rich EO, Liebow M, Srinivason M, Parish D, Wolliscroft JO, Fein O, Blaser R. Medicare financing of graduate medical education - Intractable problems, elusive solutions. J Gen Intern Med 2002 Apr; 17(4):283-92.
    View PubMed
18. Harewood GC, Wiersema MJ, Edell ES, Liebow M. Cost-minimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy. Mayo Clin Proc 2002 Feb; 77(2):155-64.
    View PubMed
19. Liebow M. The Clinton Health Plan: A Slightly Informed Speculation Saint Francis Medical Proceedings 1993; 3(3):7-9.
20. Liebow M. Practice guidelines: wave of the future? Saint Francis Medical Proceedings 1991; 2(1):11-2.
21. Yang GJC, Liebow M. Chemotherapy for metastatic non-small cell carcinoma Saint Francis Medical Proceedings 1990; 1(2):14-5.